Key players in the animal parasiticide industry are focusing continuously on expanding their geographic presence by means of acquiring local market players. Acquisition of animal health assets of local payers by major market players enabled major market players to increase their presence across various geographic regions as well as to expand its animal health product portfolio.
During 2014-2017, major players adopted mergers & acquisitions to strengthen their product portfolio, widen their customer base, and increase their footprints across the globe, followed by product launches, expansions, and agreements, partnerships, and collaborations.
Some major mergers and acquisitions are below:
- In March 2015, Perrigo Company PLC (US) acquired Omega Pharma Invest N.V. (Belgium) for USD 4.61 million. This acquisition helped the company to enhance its presence across the globe
- Zoetis, Inc. (US) acquired animal health assets of Abbott Laboratories (US) for USD 255 million, in February 2015. This acquisition expanded Zoetis’ companion animal product portfolio
- In January 2015, Eli Lilly and Company (US) acquired Novartis Animal Health (Switzerland). This acquisition helped the company strengthen its product portfolio and expanded its global commercial presence.
- In April 2014, Vetoquinol S.A. (France) acquired the animal health business of Bioniche Life Sciences Inc. (Canada). This acquisition helped Vetoquinol to leverage its existing animal healthcare product portfolio as well as its geographic presence.
The key players operating in the animal parasiticides market are Bayer AG (Germany), Boehringer Ingelheim (Germany), Ceva Sante Animale (France), Eli Lilly and Company (US), Merck and Co., Inc. (US), Zoetis, Inc. (U.S.), Sanofi (France), Virbac (France), Vetoquinol S.A. (France), Perrigo Company PLC (Ireland), Dechra Pharmaceuticals Plc (UK), and Huvepharma (Bulgaria).
To Know More @ https://www.marketsandmarkets.com/Market-Reports/animal-parasiticide-market-258895412.html
